Course: Comparison of mRNA-1273 and BNT162b2 Vaccines on Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Death During the Delta-Predominant Period
CME Credits: 1.00
Released: 2022-01-20
Immune responses to mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) vaccines decline by 6 months after vaccination, although antibody titers are higher with mRNA-1273., Comparison of vaccinated nonimmunocompromised adults showed lower risk of hospitalization for recipients of mRNA-1273 than BNT162b2 during March-August 2021. This study examined breakthrough infections, hospitalizations, and mortality in a general population for these 2 vaccines during the Delta period while considering risk characteristics of vaccine recipients and the varying time since vaccination.
Educational Objective
To identify the key insights or developments described in this article
View Full Course